Adroit-Metis LLC is a life sciences regulatory strategy and technology firm. We combine deep regulatory expertise with purpose-built technology platforms to move biopharma, medtech, and life sciences programs forward: faster, smarter, and with full ownership handed back to our clients at every step.
Pre-Work, Architecture, Tools, Handoff. Our flagship platforms are built on the proprietary PATH framework and designed so every engagement ends with complete client ownership, not vendor dependency.
Regulatory strategy and submission-readiness support that structures the path from development milestones through approval, with a full suite of tools spanning every phase of the process.
Strategic and diligence-oriented tools that help sponsors and investors evaluate, structure, and de-risk life sciences investment decisions.
Global risk management program architecture covering REMS (US), RMP (EU), and risk management frameworks for the rest of the world. We convert risk management into strategy management.
Smarter PATH™ to Risk Management designs the program. For sponsors who need it operated as well as architected, we deliver the full operational layer under Adroit-Metis oversight and reporting.
Our system accomplishes the goals set forth in the FDA CodEx initiative, and is the premier choice in full service, integrated REMS administration support today, for individual and shared REMS alike.
Eliminating the quality concerns and exorbitant cost associated with legacy options, Smarter PATH™ to Risk Management is truly fresh air in a very heavy space. It is led by some of the industry's most innovative subject matter experts, people with the lived experience of stagnant solutions that keep building on yesterday's mold of high activity cost.
That depth extends well beyond the platform. Adroit-Metis brings extensive experience in regulatory agency engagement support, preparing sponsors for and guiding them through agency interactions on program design, modification and assessment. We pair that with strategic guidance that treats risk management as part of the commercial plan rather than a cost of doing business, and with active industry collaboration alongside the organizations working to advance innovation in the REMS space.
We always knew there had to be a better way, and we were right.
Three platforms, each built for a problem the industry has been solving by hand.
Not your average QMS: a full closed-loop quality chain, including nonconformance, CAPA, change control, controlled documents, training, audits, suppliers, and risk, under one compliant control layer.
Then it adds two things most quality systems do not have: an advisory AI that respects the compliance model, and a collaboration layer that captures the reasoning behind your decisions as reusable corporate knowledge.
Tracking the path of rare disease.
A rare disease intelligence platform built for sponsors, investors, and advocacy stakeholders navigating the rare disease landscape. Patient, observant, and quietly relentless in surfacing the insights that matter.
A global women's health intelligence platform built on a "Women as Default" thesis, helping organizations identify and close gaps in sex-specific research, funding, and reporting across the global health landscape.
Beyond our platforms, our team provides regulatory strategy and technology consulting for biopharma sponsors, private equity and venture investors, and life sciences organizations. Tailored engagements built around each client's specific program needs.
Experienced, on-demand executive leadership for organizations that need senior capability now. Available across: